$54.99−3.20 (−5.50%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
10x Genomics (TXG) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~7.0%/yr (FY21→FY25), net margin −6.8%. Worth your attention in FY25: Share count (+13.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲5.2%
642.8
FY21→FY25CAGR +7.0%/yr
Net income ($M)▲76.2%
−43.5
FY21→FY25CAGR —
Free cash flow ($M)—
130.1
FY21→FY25CAGR —
Diluted EPS▲77.0%
−0.35
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+13.1%
110.3mn → 124.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$5.9M
−52.1% YoY in FY25 · 0.9% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-7¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 84.9% → 69.1%. Net margin -6.8% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 618.6 | 642.8 | 610.8 | 618.7 | 516.4 | 490.5 | ▲5.2% | +7.0% |
Cost of revenue | 173.9 | 198.9 | 196.3 | 209.4 | 120.4 | 74.1 | ▲1.3% | +28.0% |
Gross profit | 444.6 | 443.9 | 414.5 | 409.3 | 396.0 | 416.4 | ▲7.1% | +1.6% |
Research & development | 222.5 | 238.6 | 264.7 | 331.3 | 265.7 | 211.8 | ▼9.8% | +3.0% |
Selling, general & admin | 297.7 | 316.1 | 344.3 | 343.3 | 298.3 | 257.6 | ▼8.2% | +5.3% |
Total operating expenses | 516.8 | 504.9 | 609.0 | 674.6 | 564.0 | 468.7 | ▼17.1% | +1.9% |
Operating incomefeeds ROC rank | −72.2 | −61.0 | −194.6 | −265.3 | −167.9 | −52.3 | ▲68.7% | — |
Other income, net | 7.0 | 21.1 | 16.9 | 16.6 | 6.0 | −1.5 | — | — |
Pretax income | −65.2 | −39.9 | −177.7 | −248.8 | −162.0 | −53.7 | ▲77.5% | — |
Income tax | 1.9 | 3.6 | 4.9 | 6.3 | 4.0 | 4.5 | ▼26.2% | −5.2% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −67.1 | −43.5 | −182.6 | −255.1 | −166.0 | −58.2 | ▲76.2% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.52 | −0.35 | −1.52 | −2.18 | −1.46 | −0.53 | ▲77.0% | — |
Diluted shares (mn) | 130.81 | 124.75 | 120.45 | 117.17 | 113.86 | 110.35 | ▲3.6% | +3.1% |
| Margins | ||||||||
Gross margin61st pct in Healthcare | 71.9% | 69.1% | 67.9% | 66.2% | 76.7% | 84.9% | ▲1.2pp | −15.8pp |
Operating margin | −11.7% | −9.5% | −31.9% | −42.9% | −32.5% | −10.7% | ▲22.4pp | +1.2pp |
Net margin27th pct in Healthcare | −10.8% | −6.8% | −29.9% | −41.2% | −32.1% | −11.9% | ▲23.1pp | +5.1pp |
† TTM = trailing four quarters through 2026-09-30.
4 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was 10x Genomics' revenue last fiscal year?
10x Genomics reported revenue of $642.8M in fiscal 2025, up 5.2% from fiscal 2024.
What was 10x Genomics' net income?
10x Genomics reported net income of −$43.5M in fiscal 2025, a net margin of −6.8%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

